

ASX RELEASE

Major UK Project Moves to Implement VolparaDensity™ Software into NHS Breast Screening Programme in England

Highlights

- **VolparaDensity™ software implementation trial is the next step towards potential further rollout of density and risk-based screening across England**
- **Implementation trial to take place in Greater Manchester, East Cheshire and East Lancashire regions— and is part of PROCAS 2 Programme Grant funded by National Institute for Health Research (NIHR)**
- **England’s breast screening programme is one of world’s largest, imaging 2M women a year**
- **Volpara selected following its use in the PROCAS 1 study, which recruited participants over a 66-month period from the Greater Manchester Breast Screening Programme**

Wellington, NZ, 19 February 2018: [Volpara Health Technologies](#) (“Volpara”; ASX: VHT), a digital health company focused on early detection of breast cancer by improving the quality of screening, is pleased to announce the commencement of a major trial to implement VolparaDensity™ software and risk-based screening into the NHS Breast Screening Programme in England. The implementation trial is part of the PROCAS 2 Programme Grant “Providing breast cancer risk information as part of national breast cancer screening programme: building an evidence base on benefits and harms to inform a decision to implement”. The grant will be run from the Manchester University NHS Foundation Trust (MFT) from funding by the NIHR, which aims to improve the health and economy of the UK.

In the implementation trial, all consenting women screened for breast cancer in the Greater Manchester, East Cheshire and East Lancashire regions will receive breast cancer risk information based on a risk assessment incorporating mammographic density estimated by VolparaDensity™ software. The trial will run for two years with an initial consultation period. An agreement has now been signed between VHT and the Manchester University NHS Foundation Trust, to address data governance and system design, before moving to deploy across six sites, covering over 8,000 women.

The trial is the next step toward potentially including Volpara’s technology for breast density and risk-based screening as routine across the public breast cancer screening program in England—one of the world’s largest screening programs, covering two million women annually. It is the second stage of the Predicting Risk of Cancer at Screening (PROCAS) study undertaken, with the aim of enhancing the NHS Breast Screening Programme by including breast cancer risk prediction for women when they attend routine breast screening.

The original study as part of stage one, led by Professor Gareth Evans, investigated women’s personal breast cancer risk based on breast density, lifestyle, reproductive information and family history.

“PROCAS is a very important study that will change the way breast screening is approached in the UK and globally, and will ensure women better understand their risk and high-risk patients are offered appropriate screening options,” said Dr Ralph Highnam, CEO of Volpara Health Technologies.

“To be selected as the tool of choice for measurement of breast density is an important validation of our work and competitive advantage. Following the data consultation and trial implementation, it is hoped that breast density measurement, using VolparaDensity™ software, will be adopted as routine across the NHS Breast Screening Programme.”

ENDS.

For further information, please contact:

Ralph Highnam, CEO
Volpara Health Technologies
ralph.highnam@volparasolutions.com
t: +64 21 149 0541

Kyahn Williamson
WE Buchan
kwilliamson@we-buchan.com
t: +61 3 9866 4722

About Volpara Health Technologies Limited (ASX: VHT)

Founded in 2009 from research originally conducted at Oxford University, and based in Wellington, New Zealand, VHT facilitates the early detection of breast cancer through its digital health solutions to enable personalised, high-quality breast cancer screening based on automated, objective measurements of breast density.

VHT has numerous patents and trademarks and regulatory clearances, including FDA and CE, supporting its technology and services. An ASX-listed company that raised A\$20M through an IPO and subsequent share placement and rights issue in 2016, VHT has customers and/or research projects in 36 countries.

www.volparasolutions.com

About the UK National Institute for Health Research (NIHR):

Established by the Department of Health, the NIHR aims to improve the health and wealth of the nation through research by:

- funds high quality research to improve health
- trains and supports health researchers
- provides world-class research facilities
- works with the life sciences industry and charities to benefit all
- involves patients and the public at every step

For personal use only